Contact this trialFirst, we need to learn more about you.
Janus Kinase Inhibitor
Ruxolitinib XR vs IR for Healthy Participants
Recruiting1 awardPhase 1
Tempe, Arizona
"This trial aims to compare whether a new form of Ruxolitinib medication taken as a 55 mg extended-release tablet works the same as the current immediate-release tablets when given to healthy individuals."
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.